Overview

* Oncology Institute ( TOI ) Q2 revenue rises 21.5% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EBITDA improves to $(4.1) mln from $(8.7) mln in prior year

* Co's revenue growth driven by 40% increase in pharmacy business and new capitated lives

Outlook

* Oncology Institute ( TOI ) reaffirms 2025 revenue guidance of $460 to $480 mln

* Company expects 2025 gross profit between $73 mln and $82 mln

* Oncology Institute anticipates Q3 2025 adjusted EBITDA of $(2.5) to $(3.5) mln

Result Drivers

* PHARMACY GROWTH - Pharmacy business grew over 40% year-over-year, driving revenue increase, according to CEO Daniel Virnich

* CAPITATED LIVES - Addition of over 50,000 new capitated lives boosted value-based business revenue

* GEOGRAPHIC EXPANSION - Ongoing expansion into new Florida regions with a major health plan expected to double covered lives for that payor

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $119.80 $114.60

Revenue mln mln (2

Analysts

)

Q2 Net -$17 mln

Income

Q2 Gross $17.50

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Oncology Institute Inc ( TOI ) is $7.00, about 41.3% above its August 12 closing price of $4.11

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)